Bange et al. reported that COVID-19 patients with hematologic cancer who has COVID-19-specific INF-gamma response showed improved mortality even in limited humoral immunity condition [19], and they pointed out the importance of the CD8 T cell response to vaccination. The gene discussed is CD8A; the disease is hematopoietic and lymphoid cell neoplasm.